Fresh from the pipeline - Rosuvastatin calcium

被引：65

作者：

Quirk, J ^{[1
]}

Thornton, M ^{[1
]}

Kirkpatrick, P ^{[1
]}

机构：

[1] Decis Resources Int, London WC1B 4HQ, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2003年 / 2卷 / 10期

关键词：

D O I：

10.1038/nrd1205

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Rosuvastatin calcium (Crestor; AstraZeneca), the seventh drug in the statin class, was approved by the US FDA in August 2003 for the reduction of cholesterol levels in patients with hypercholesterolaemia. Billed as the most potent statin available, can it overcome initial setbacks and make a significant impact in the multi-billion-dollar market for cholesterol-lowering drugs?

引用

页码：769 / 770

页数：2

共 50 条

[21] Rosuvastatin calcium
Jeremy Quirk
Mark Thornton
Peter Kirkpatrick
[J]. Nature Reviews Drug Discovery, 2003, 2 : 769 - 770
[22] Rosuvastatin calcium
不详
[J]. DRUGS OF THE FUTURE, 2002, 27 (01) : 96 - 101
[23] Fresh from the biotech pipeline—2019
Chris Morrison
[J]. Nature Biotechnology, 2020, 38 : 126 - 131
[24] Erratum: Fresh from the pipeline 2011
Jim Kling
[J]. Nature Biotechnology, 2012, 30 (4) : 365 - 365
[25] Fresh from the biologic pipeline—2009
Cormac Sheridan
[J]. Nature Biotechnology, 2010, 28 : 307 - 310
[26] Fresh from the biotech pipeline—2018
Chris Morrison
[J]. Nature Biotechnology, 2019, 37 : 118 - 123
[27] Fresh from the biotech pipeline—2015
Chris Morrison
[J]. Nature Biotechnology, 2016, 34 : 129 - 132
[28] Fresh from the biotech pipeline—2016
Chris Morrison
[J]. Nature Biotechnology, 2017, 35 : 108 - 112
[29] Fresh from the biotech pipeline—2014
Chris Morrison
[J]. Nature Biotechnology, 2015, 33 : 125 - 128
[30] Fresh from the biologic pipeline—2010
Jim Kling
[J]. Nature Biotechnology, 2011, 29 : 197 - 200

← 1 2 3 4 5 →